Answers are grounded in this paper and cite their sources.
AIMS: To characterize body-composition evidence and muscle and safety gaps for testosterone replacement therapy (TRT) added to incretin treatment in men with overweight or obesity and hypogonadism. MATERIALS AND METHODS: PROSPERO CRD420261489220. Seven databases and two registries were searched through 4 September 2026; citations were checked on 10 September. Eligible studies compared concurrent TRT with a comparable incretin regimen without TRT or examined baseline androgen status longitudinally. The original eight reports underwent independent assessment. Following joint initial screening, 300 randomly sampled units were independently rescreened. ROBINS-I, RoB 2 and GRADE informed synthesis by design and outcome. RESULTS: Two reports provided non-equivalent body-composition outcomes with very low certainty. Neither established incremental TRT benefit. In a nonrandomized pilot (five men per group), the final DXA lean-mass difference was +2.70 kg (exploratory, unadjusted 95% CI -1.75 to +7.15); the descriptive difference in changes was +2.1 kg, with change-score dispersion unavailable. A randomized conference report (266 men across five arms; comparison-arm sizes unavailable) attributed 26% versus 38% of weight loss to fat-free mass with versus without TRT. These observations do not corroborate a common biological effect. No usable TRT-specific strength, function or safety comparisons or eligible baseline-androgen analyses were identified. Two unclassified registry entries limit completeness. CONCLUSIONS: Available evidence does not establish incremental TRT benefit for body composition or muscle outcomes. Missing functional and safety evidence remains a central gap. TRT solely for lean-tissue preservation is unsupported.
No takes yet. Share an insight, caveat, or question.
Bruna-Mejías et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: